ISTANBUL — November 13, 2026 -- Four hair loss drugs are in clinical trials, but as of November 2026 none has regulatory approval for pattern hair loss. Smile Hair Clinic, an Istanbul hair transplant provider, set out where each candidate stands in a briefing from its co-founders, Dr. Mehmet Erdoğan and Dr. Gökay Bilgin.
For readers weighing a transplant against waiting, the practical point is this: none of the four can be prescribed as an approved treatment today. By our count, two of the four have reported Phase III results, and only one has a stated filing plan.
Two candidates have late-stage results and one has a filing date
- Topical anti-androgen: completed Phase III with positive efficacy and safety findings, according to the release. A US FDA filing is planned for early 2027.
- Extended-release oral minoxidil: positive Phase III results in men, including 12-month data on hair count and coverage. Results from a registration-directed study in women are expected in the first half of 2027.
- Topical stem-cell candidate: in a Phase II/III trial in men after encouraging Phase IIa findings.
- Antibody candidate: has completed a Phase II study in men with androgenetic alopecia. Public efficacy results are limited.
A filing is not an approval. "A filing date marks the start of the regulatory process, not its completion," Erdoğan said. He warned that a year like 2027 should not be read as a promise of availability.
Smile says medication and transplants do different jobs
Medical treatments act on existing follicles. A transplant moves selected follicles from a donor area to parts of the scalp that need coverage. Smile performs Sapphire FUE and DHI transplants for international patients.
Bilgin says medication may help thicken thinning hair and slow further loss when started early. Areas of substantial, long-standing loss may still need a transplant, he says. A transplant also does not stop surrounding native hair from thinning later.
The release gives no price, launch date or suitability criteria for any of the four candidates. Smile's co-founders say the choice between treatment, waiting and surgery should follow a physician's assessment of the type and stage of hair loss, the condition of existing follicles and donor capacity.
The next scheduled data point is the women's registration-directed minoxidil study, with results expected in the first half of 2027.